Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.
about
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseasePhosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseasePulmonary rehabilitation for chronic obstructive pulmonary diseaseChemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilastPDE4 inhibitors: current statusPhosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysisThe cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory DiseasesRoflumilast: a review of its use in the treatment of COPDA rational approach to single, dual and triple therapy in COPDPositioning new pharmacotherapies for COPDIs there still hope for single therapies: how do we set up experimental systems to efficiently test combination therapies?Optimizing management of chronic obstructive pulmonary disease in the upcoming decade.Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysisThe selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in micePrevention of COPD exacerbations: medications and other controversiesDrug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.COPD exacerbations. 4: PreventionCounterpoint: were industry-sponsored roflumilast trials appropriate? No.Chronic obstructive pulmonary disease: towards pharmacogenetics.Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.p38 mitogen-activated protein kinase determines the susceptibility to cigarette smoke-induced emphysema in mice.Aging-related hyperinflammation in endotoxemia is mediated by the alpha2A-adrenoceptor and CD14/TLR4 pathways.Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trialsAirways disease: phenotyping heterogeneity using measures of airway inflammation.β2-Agonist induced cAMP is decreased in asthmatic airway smooth muscle due to increased PDE4DNo relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled studyExposing rodents to a combination of tobacco smoke and lipopolysaccharide results in an exaggerated inflammatory response in the lung.Inhibition of cyclooxygenase-2 prevents adverse effects induced by phosphodiesterase type 4 inhibitors in ratsVulnerable COPD patients with comorbidities: the role of roflumilast.Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.ABC of chronic obstructive pulmonary disease. Future treatmentsABCD of the phosphodiesterase family: interaction and differential activity in COPDUpdate on pharmaceutical and minimally invasive management strategies for chronic obstructive pulmonary disease.Measuring the impact of a live, case-based, multiformat, interactive continuing medical education program on improving clinician knowledge and competency in evidence-based COPD careImpact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.Relation between bronchial responsiveness to inhaled leukotriene D4 and markers of leukotriene biosynthesis.Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice
P2860
Q24202545-6BD81863-1EC2-4224-9103-808AE28B562FQ24234493-689999A8-F388-4FBC-B148-EBB8944832EAQ24243959-FA31B1C0-A239-4D39-A9B8-89664D14B558Q24634179-BB6F2C22-5BE6-4D96-B0AE-7F9693922580Q24646836-0C7D24D8-39FB-4315-A730-E82DBB5652C6Q24651926-CA5492BB-38F1-49BE-A473-98D7AA73AF48Q25255769-AA999F23-E4F1-4327-98C7-4E1258BAA6CCQ26740229-473F1AAA-9EF0-44DB-8F3F-6CBB0186A205Q26750377-4CF9A921-A384-4903-9EB0-1376860F6A07Q26770501-A96A5240-4825-40BA-B223-437BF204FED2Q26776477-F77FAD15-B863-4F08-93C7-9D7FDD1AFD5EQ26798659-322A05A7-3CAB-432D-A55F-EF00EF79BDEDQ26998459-D069A031-D32C-41B9-972A-A0FDD3393A5EQ27693341-04B8214B-256F-4874-9B59-DDB8EF807166Q28070108-8CD0C59C-03FE-47B2-BA0C-901BF81AEE12Q28487329-D0B591F2-EE12-42EB-A0E5-65C0661FDDA1Q28596774-051E9AA5-9754-4014-9975-EEAD2D8AA799Q30249747-912DCC9F-4535-4EE5-91AD-DF5D7981D7B5Q30480789-0BF34811-187E-44E9-ACA9-346DD5D15DC4Q33572575-5AB746B1-3156-47D4-AECF-B0FCA4CFE7FDQ33600138-DD2C872C-C55F-48CB-976E-486DDA167E01Q33624262-1A52A0F8-F3FD-48A0-8DCA-4CE28B8690BDQ33624820-084BBDA6-5B4B-40CD-B25D-404AA05068A8Q33808323-C6AA34C5-3B5C-4EE3-86E8-07210BAADCFEQ33824534-3A863A48-DB6C-43C6-A6D7-3118973A199CQ33864952-B78E8F42-47B0-48E7-AE51-5E3B7ED40BDCQ33911113-0329342D-70D3-43A1-8EE6-F488BD10D847Q33919207-459E6C53-379D-45E8-966E-5D84EFDD9A25Q34219585-372C4C32-47DC-4229-A105-9C48306058BDQ34540209-51F03B3E-D28C-4B37-A460-ADA2600C2D82Q34566361-D6A23E15-C318-4D30-AB02-40E890BF13DAQ34578865-E102FBB7-46D2-499E-9F05-74112A95D708Q34873343-BE4D286F-22F6-4386-BFB1-D19FE99D6FCAQ34961511-7C4B3EBF-1334-48E4-95BB-B1DD380274F1Q35028812-1F711958-FC41-47A3-BDCE-7F643B5669F8Q35056998-98DA7E90-C7D2-467A-B773-0369208194A9Q35194591-24EB7C0A-ADF4-45FB-9B07-35B7341BDFB3Q35377816-DB5B2270-2F73-47BC-B5B6-8B8AF014D652Q35537297-26670F62-0D7F-4E90-B2DC-640F0489B005Q35658509-7E8416B1-A8A0-44D2-9300-36F5D3AFF41C
P2860
Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Roflumilast--an oral anti-infl ...... a randomised controlled trial.
@en
Roflumilast--an oral anti-infl ...... a randomised controlled trial.
@nl
type
label
Roflumilast--an oral anti-infl ...... a randomised controlled trial.
@en
Roflumilast--an oral anti-infl ...... a randomised controlled trial.
@nl
prefLabel
Roflumilast--an oral anti-infl ...... a randomised controlled trial.
@en
Roflumilast--an oral anti-infl ...... a randomised controlled trial.
@nl
P2093
P1433
P1476
Roflumilast--an oral anti-infl ...... a randomised controlled trial.
@en
P2093
Denis O'Donnell
Dirk Bredenbröker
Eric D Bateman
Klaus F Rabe
Stephan Witte
Thomas D Bethke
P304
P356
10.1016/S0140-6736(05)67100-0
P407
P577
2005-08-01T00:00:00Z